Patient and disease characteristics of matches
. | SHDT . | CT . | P . |
|---|---|---|---|
| n | 44 | 44 | |
| Age at study entry,* y (range) | 52 (40-64) | 54 (44-63) | |
| Age at diagnosis, y (range) | 49 (38-62) | 52 (42-60) | .20 |
| Binet stage at study entry*(%) | |||
| A | 13 (30) | 13 (30) | |
| B | 21 (48) | 21 (48) | |
| C | 10 (23) | 10 (23) | |
| Binet stage at diagnosis (%) | .63 | ||
| A | 22 (50) | 22 (50) | |
| B | 15 (34) | 14 (32) | |
| C | 5 (11) | 2 (5) | |
| Not available | 2 (5) | 6 (14) | |
| Lymphocyte count higher than 50 × 109/L* (%) | 25 (57) | 25 (57) | |
| VH homology less than 98%* (%) | 15 (34) | 15 (34) | |
| 11q deletion (%) | 7/34 (21) | 12 (27) | .60 |
| 17p deletion | 0 | 0 | |
| CD38+ more than 30% of CLL cells (%) | 16/31 (52) | 12/25 (48) | .99 |
| Female sex (%) | 12 (27) | 15 (34) | .64 |
| Symptomatic disease at study entry (%) | 32 (73) | 34 (77) | .81 |
| Months from diagnosis to symptoms | |||
| All patients, log rank | 18 | 30 | .12 |
| Symptomatic patients, Mann-Whitney U (range) | 7 (1-89) | 12 (1-136) | .65 |
| Months from diagnosis to study entry (range) | 16 (0-113) | 22 (0-106) | .52 |
| Chemotherapy naive at study entry (%) | 32 (73) | 28 (63) | .49 |
| Previous exposure to fludarabine (%) | 2 (5) | 2 (5) | .99 |
| Year of study entry (range) | 1998 (1994-2001) | 1994 (1991-1998) | <.001 |
. | SHDT . | CT . | P . |
|---|---|---|---|
| n | 44 | 44 | |
| Age at study entry,* y (range) | 52 (40-64) | 54 (44-63) | |
| Age at diagnosis, y (range) | 49 (38-62) | 52 (42-60) | .20 |
| Binet stage at study entry*(%) | |||
| A | 13 (30) | 13 (30) | |
| B | 21 (48) | 21 (48) | |
| C | 10 (23) | 10 (23) | |
| Binet stage at diagnosis (%) | .63 | ||
| A | 22 (50) | 22 (50) | |
| B | 15 (34) | 14 (32) | |
| C | 5 (11) | 2 (5) | |
| Not available | 2 (5) | 6 (14) | |
| Lymphocyte count higher than 50 × 109/L* (%) | 25 (57) | 25 (57) | |
| VH homology less than 98%* (%) | 15 (34) | 15 (34) | |
| 11q deletion (%) | 7/34 (21) | 12 (27) | .60 |
| 17p deletion | 0 | 0 | |
| CD38+ more than 30% of CLL cells (%) | 16/31 (52) | 12/25 (48) | .99 |
| Female sex (%) | 12 (27) | 15 (34) | .64 |
| Symptomatic disease at study entry (%) | 32 (73) | 34 (77) | .81 |
| Months from diagnosis to symptoms | |||
| All patients, log rank | 18 | 30 | .12 |
| Symptomatic patients, Mann-Whitney U (range) | 7 (1-89) | 12 (1-136) | .65 |
| Months from diagnosis to study entry (range) | 16 (0-113) | 22 (0-106) | .52 |
| Chemotherapy naive at study entry (%) | 32 (73) | 28 (63) | .49 |
| Previous exposure to fludarabine (%) | 2 (5) | 2 (5) | .99 |
| Year of study entry (range) | 1998 (1994-2001) | 1994 (1991-1998) | <.001 |
Matching variables.